JERUSALEM, Sept. 1 (Xinhua) -- Israeli researchers have developed a novel strategy for a type of lung cancer with limited treatment options, the Israel Institute of Technology (Technion) said in a statement on Sunday. In a study published in Nature Communications, the Technion researchers focused...
Reports on the optimism of oncologists participating in the eighth World Congress on Lung Cancer held in Dublin, Ireland in August 1997. The advances in chemotherapy, including a trial with topotecan; The combination treatment of topotecan and paclitaxel for patients with small-cell lung cancer (...
The work being carried out by Combes and his colleagues offers new hope. They are working to improve the delivery to cells of so-called therapeutic mRNA as a treatment for lungcancer. This method is a more targeted and effective treatment approach. You have probably heard that mRNA technology ...
Lung cancer is the second most common type of cancer in the U.S., accounting for more deaths than breast, prostate andcolon cancercombined, according to theCenters for Disease Control and Prevention. Many people endure more than one type of lung cancer treatment, which can last for weeks to...
MIT cancer biologists have identified a new therapeutic target for small cell lung cancer, an especially aggressive form of lung cancer with limited options for treatment.
"The light activates the drug, and the drug that is now in the cells directly kills the cancer cells," Dr. Ross said. In an X-ray, a lung on the left before treatment looks white, because there's no air flow. With photodynamic therapy, the tumor is killed, which then allows air ...
sooner. Understanding the genetic faults that drive each individual patient's cancer will help to make sure they get the right treatment for their disease, at the right time. This is exactly the kind of work that will take place in the new Manchester Cancer Research Centre currently being ...
Lung CancerEttinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991; 7: 113-22.Ettinger DS. New drugs in the treatment of non-small cell lung cancer. Lung Cancer 1991;7: 113–122.Ettinger DS. New drugs in the treatment of non-small cell lung cancer. ...
If 10 years ago you were talking about defining a five-year survival rate for metastatic non-small celllung cancer patients, someone would laugh in your face. It would be a joke. It's just a very different time now," he said of the progress being made in the treatment of lung cancer...
The treatment could prolong the lives of lung cancer patients an average of 50 percent over patients receiving placebos. They survived another 3.3 months on average, said Han Baohui, who led the clinical trials involving 437 patients at 34 health centers and hospitals nationwide. ...